Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Karen BräutigamElodie Kabore-WolffAhmad Fawzi HussainStephan PolackAchim RodyLars HankerFrank KösterPublished in: Journal of cancer research and clinical oncology (2021)
In conclusion, combination of PD-1/PD-L1 and ERK1/2 inhibitors showed favorable effects for a new therapy strategy, with better results in TNBC cell lines than in non-TNBC cells. The effects have to be validated in models that can reflect the interaction between immune and tumor cells like the situation in the tumor micro-environment.